The best competition has to offer 72% CR and 59% durable CR response at 12 months or better. Combination of N-803 with BCG. Combination drugs offer uneven comparison but gives us an idea of the most competitive treatment modality. This is still many more treatments using standard BCG protocol plus N-803 so about 12-15 treatments or more and has more side effects. But still very good outcome. If we match or beat their numbers we will shine as the next gold standard. Imo. Much more patient friendly just can't afford any screw ups.
https://immunitybio.com/category/press-releases/